Neon Therapeutics’ $100 Million Initial Public Offering

Goodwin advised Neon Therapeutics on the deal Neon Therapeutics (“NTGN”), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, closed its public offering of 6,250,000 shares of common…